AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Lisata Therapeutics Statistics
Share Statistics
Lisata Therapeutics has 8.39M shares outstanding. The number of shares has increased by 1.05% in one year.
Shares Outstanding | 8.39M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.91% |
Owned by Institutions (%) | n/a |
Shares Floating | 6.92M |
Failed to Deliver (FTD) Shares | 614 |
FTD / Avg. Volume | 2.23% |
Short Selling Information
The latest short interest is 17.06K, so 0.2% of the outstanding shares have been sold short.
Short Interest | 17.06K |
Short % of Shares Out | 0.2% |
Short % of Float | 0.25% |
Short Ratio (days to cover) | 1.79 |
Valuation Ratios
The PE ratio is -1.06 and the forward PE ratio is -1.15.
PE Ratio | -1.06 |
Forward PE | -1.15 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | 0.46 |
P/FCF Ratio | -1.1 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lisata Therapeutics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.18, with a Debt / Equity ratio of 0.01.
Current Ratio | 8.18 |
Quick Ratio | 8.18 |
Debt / Equity | 0.01 |
Total Debt / Capitalization | 0.63 |
Cash Flow / Debt | -65.68 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.43% and return on capital (ROIC) is -47.97%.
Return on Equity (ROE) | -0.43% |
Return on Assets (ROA) | -0.38% |
Return on Capital (ROIC) | -47.97% |
Revenue Per Employee | 0 |
Profits Per Employee | -833.60K |
Employee Count | 25 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | -2.33M |
Effective Tax Rate | 0.1 |
Stock Price Statistics
The stock price has increased by 26.53% in the last 52 weeks. The beta is 1.22, so Lisata Therapeutics 's price volatility has been higher than the market average.
Beta | 1.22 |
52-Week Price Change | 26.53% |
50-Day Moving Average | 2.98 |
200-Day Moving Average | 3.05 |
Relative Strength Index (RSI) | 66.59 |
Average Volume (20 Days) | 27.50K |
Income Statement
Revenue | n/a |
Gross Profit | -189.00K |
Operating Income | -25.71M |
Net Income | -20.84M |
EBITDA | -25.52M |
EBIT | n/a |
Earnings Per Share (EPS) | -2.58 |
Balance Sheet
The company has 22.59M in cash and 305.00K in debt, giving a net cash position of 22.29M.
Cash & Cash Equivalents | 22.59M |
Total Debt | 305.00K |
Net Cash | 22.29M |
Retained Earnings | -528.08M |
Total Assets | 38.20M |
Working Capital | 33.00M |
Cash Flow
In the last 12 months, operating cash flow was -20.03M and capital expenditures 0, giving a free cash flow of -20.03M.
Operating Cash Flow | -20.03M |
Capital Expenditures | 0 |
Free Cash Flow | -20.03M |
FCF Per Share | -2.48 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
LSTA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -69.35% |
FCF Yield | -64.18% |
Analyst Forecast
The average price target for LSTA is $15, which is 303.2% higher than the current price. The consensus rating is "Buy".
Price Target | $15 |
Price Target Difference | 303.2% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Sep 15, 2022. It was a backward split with a ratio of 1:15.
Last Split Date | Sep 15, 2022 |
Split Type | backward |
Split Ratio | 1:15 |
Scores
Altman Z-Score | -17.06 |
Piotroski F-Score | 1 |